Skip to main content

AAV vectors- Pursuing a one-time therapy for ocular diseases

In the ground-breaking realm of gene therapy, adeno-associated virus (AAV) vectors are revolutionizing our approach to treating ocular diseases. In this white paper, 'AAV vectors: Pursuing a one-time therapy for ocular diseases,' we discuss with Professor Dominik Fischer, a renowned Ophthalmic Surgeon and Professor of Ophthalmology, the remarkable potential and challenges of developing AAV gene therapies in ocular disorders. Learn about the critical challenges of ensuring long-term gene expression, the durability of these therapies, and innovative strategies to enhance treatment effectiveness while managing potential toxicity. This white paper is an essential read for anyone interested in the latest advancements in gene therapy and its transformative impact on ocular health.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

AAV vectors- Pursuing a one-time therapy for ocular diseases

Download Whitepaper